Long-Term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-Severe Dementia Associated With Parkinson's Disease (PDD) - Related Studies

Long-Term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-Severe Dementia Associated With Parkinson's Disease (PDD)

This study is currently recruiting participants.

Study NCT00623103. Last updated on November 20, 2008. Information provided by Novartis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Dementia
		Parkinson Disease

2	More general conditions related to this trial
		Basal Ganglia Diseases
		Brain Diseases
		Central Nervous System Diseases
		Delirium, Dementia, Amnestic, Cognitive Disorders
		Mental Disorders
		Movement Disorders
		Nervous System Diseases
		Neurodegenerative Diseases
		Parkinsonian Disorders

3	Interventions listed in this trial
		Rivastigmine capsule
		Rivastigmine transdermal patch

4	Additional drug interventions recognized in this trial
		Rivastigmine

5	More general drug interventions related to this trial
		Central Nervous System Agents
		Cholinergic Agents
		Cholinesterase Inhibitors
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Neuroprotective Agents
		Neurotransmitter Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protective Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Novartis